Search clinical trials for: Endocrine sensitive

Total 28294 results

Peking University First Hospital

Not yet recruiting

Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer

Prostate Adenocarcinoma
The University of Hong Kong

Recruiting

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer (SCENIC)

Recurrent Ovarian Carcinoma

Hong Kong
West China Second University Hospital

Recruiting

Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients

Ovarian Cancer

China
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
Steno Diabetes Center Copenhagen

Recruiting

The ACCT2 Study Individuals With Type 2 Diabetes and Non-Western Backgrounds (ACCT2) (ACCT2)

Type 2 Diabetes

Denmark
University Hospital Padova

Recruiting

Water and Electrolytes Content in HYpertension (WHYSKI) in the SKIn (WHYSKI)

Hypertension | Essential Hypertension | Hyperaldosteronism | Aldosteronism | Conn Adenoma | Aldosterone Disorder | Aldosterone-producing Adenoma | Bilateral Adrenal Hyperplasia

Italy
UK Kidney Association

Recruiting

National Registry of Rare Kidney Diseases (RaDaR)

Vasculitis | AL Amyloidosis | Tuberous Sclerosis | Fabry Disease | Cystinuria | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Bartter Syndrome | Pure Red Cell Aplasia | Membranous Nephropathy | Atypical Hemolytic Uremic Syndrome | Autosomal Dominant Polycystic Kidney Disease | Cystinosis | Nephronophthisis | BK Nephropathy and other conditions

United Kingdom
Lan Coffman
National Cancer Institute (NCI); MorphoSys AG

Recruiting

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

United States
Assiut University

Not yet recruiting

Evaluation of Serum Pentraxin 3 and High Sensitive CRP in Female Patients With Gestational Diabetes Mellitus in Second Trimester of Pregnancy

Gestational Diabetes Mellitus in Second Trimester of Pregnancy
Chongqing University Cancer Hospital

Recruiting

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Ovarian Cancer

China
Instituto Mexicano del Seguro Social
Instituto Nacional de Salud Publica, Mexico; Universidad Nacional Autonoma... and other collaborators

Recruiting

Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy (EA&DPN)

Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy | Acupuncture | Diabetic Polyneuropathy | Electroacupuncture | Nerve Conduction

Mexico
Fudan University
BGI Tianjin

Recruiting

Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer (EOC)

Ovarian Cancer

China
Peking Union Medical College Hospital
Zai Lab (Shanghai) Co., Ltd.

Not yet recruiting

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi (t)

Epithelial Ovarian Cancer
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
University College, London
Barts & The London NHS Trust; Anticancer Fund, Belgium; JP Moulton Charitable...

Recruiting

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer (ACTOv)

Ovarian Cancer | Fallopian Tube Cancer | Relapsed Ovarian Cancer | Peritoneal Cancer | High Grade Serous Carcinoma | Ovary Cancer | Endometrioid Carcinoma

United Kingdom
Xiaoxiang Chen

Not yet recruiting

Variance of HRD From Paired Ovarian Cancer (HOPEII)

Ovarian Cancer | HRD | Platinum-sensitive Ovarian Cancer

China
CanariaBio Inc.
Korean Cancer Study Group

Recruiting

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer by FIGO Stage

Korea, Republic of
Hospices Civils de Lyon

Recruiting

NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK)

Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer

France
NRG Oncology
National Cancer Institute (NCI)

Recruiting

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (DEBRA)

Stage I Breast Cancer

United States, Canada, Hong Kong
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months (REVOCAN)

Ovarian Cancer

France
Yonsei University
Takeda

Recruiting

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor (NIRVANA-R)

Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Korea, Republic of
ARCAGY/ GINECO GROUP
Merck Sharp & Dohme LLC; OSE Immunotherapeutics

Recruiting

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (TEDOVA)

Relapsed Ovarian Cancer | Platinum-sensitive Ovarian Cancer

Belgium, France, Germany
North Eastern German Society of Gynaecological...
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (PERCEPTION)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Low Grade Serous Carcinoma

Germany
Xiaoxiang Chen

Recruiting

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (ANLOLA)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Ovarian Diseases | Adnexal Diseases | Carcinoma, Ovarian Epithelial | Ovarian Cancer | Angiogenesis | Genital Diseases, Female | Antineoplastic Agents | BRCA1... and other conditions

China
National Cancer Institute (NCI)

Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Castration-Resistant Prostate Carcinoma and other conditions

United States
Sheba Medical Center

Recruiting

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Urogenital Neoplasms | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Ovarian Diseases | Ovarian Neoplasms | Carcinoma, Ovarian Epithelial | Neoplasm of Stomach | Ovarian Epithelial Tumor

Israel
Shengjing Hospital

Recruiting

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Breast Cancer

China
Bobbie Jo Rimel, MD

Recruiting

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer

Recurrent Ovarian Cancer | Platinum-sensitive Ovarian Cancer

United States
Medical University Innsbruck

Recruiting

Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria

Recurrent Ovarian Carcinoma

Austria
Hunan Cancer Hospital

Recruiting

Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

China
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
National Cancer Institute, Naples

Recruiting

Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study (MITO 31)

BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Italy
BeiGene

Active, not recruiting

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Ovarian Cancer

China
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditions

United States
AstraZeneca

Active, not recruiting

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (L-MOCA)

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive

China, Malaysia
Pfizer

Completed

A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Breast Cancer

Denmark
ImmunoGen, Inc.

Active, not recruiting

IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Ovarian Cancer

United States, United Kingdom, Belgium, Spain, Canada, Georgia
ImmunoGen, Inc.

Active, not recruiting

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, France, Belgium, Spain, Ireland, Italy, Australia, Canada
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
AstraZeneca

Completed

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Ovarian Cancer

Canada, Czechia, Poland, Romania, United States, Belgium, France, Russian Federation, United Kingdom, Israel, Spain, Germany, Austria, Netherlands, Australia, Estonia, Ukraine
Mario Negri Institute for Pharmacological Research
North Eastern German Society of Gynaecological Oncology

Active, not recruiting

Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) (Newton)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Italy, Germany
Roswell Park Cancer Institute

Active, not recruiting

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
Aprea Therapeutics

Completed

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

United States, France, Spain, Netherlands, United Kingdom, Belgium, Germany, Sweden
AstraZeneca

Active, not recruiting

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Ovarian Cancer

United States, Czechia, Italy, Belgium, Canada, Germany, Peru, Spain, Japan, Netherlands, United Kingdom, Australia
CanariaBio Inc.
Veristat, LLC

Active, not recruiting

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Peritoneal Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Epithelial Cancer of Ovary | Recurrent Epithelial Ovarian Cancer | Recurrent Carcinoma of Ovary | Adenocarcinoma of Ovary

United States
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer AJCC v6 and v7 | Stage IV Ovarian Cancer AJCC v6 and v7 | Stage IV Primary Peritoneal Cancer AJCC v7 | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive... and other conditions

United States
University of Mostar

Completed

Relationship of Reduced Arterial Stiffness and Hs-CRP With GDM.

Gestational Diabetes

Bosnia and Herzegovina
North Eastern German Society of Gynaecological...
Center for Clinical Trials Philipps University Marburg

Active, not recruiting

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer (RESCUE)

Estrogen Receptor Positive Tumor | Primary Invasive Breast Cancer | Human Epidermal Growth Factor Receptor 2 Negative Tumor

Germany, Switzerland

Search clinical trials for: Endocrine sensitive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations